SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM...
-- New publication details Foundation Medicine’s assay’s ability to measure bTMB and to identify patients who may benefit from anti-PD-L1...
As filed with the Securities and Exchange Commission on August 3, 2018 Registration No. 333-191380...
FORM 4 [ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads